medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 1

<< Back

Ann Hepatol 2013; 12 (1)

Raloxifene hydrochloride as hepatitis C treatment

Motola-Kuba M, Méndez-Sánchez N

Language: English
References: 11
Page: 164-165
PDF size: 59.10 Kb.


Text Extraction

COMMENT
Chronic hepatitis C infections appears to progress more rapidly in men than in women, and cirrhosis is predominately a disease of men and postmenopausal women.


REFERENCES

  1. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int 2003; 23(1): 63-92.

  2. Di Martino V, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte F, Moussalli J, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004; 40: 1426-33.

  3. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010; 9: 402-9.

  4. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res 2007; 37: 239-47.

  5. Furusyo N, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T, Ikezaki H, et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol 2012; 57: 1186-92.

  6. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.

  7. Lacort M, Leal AM, Liza M, Martín C, Martínez R, Ruiz-Larrea MB. Protective effect of estrogens and catecholestrogens against peroxidative membrane damage in vitro. Lipids 1995; 30: 141-6.

  8. Watashi K, Inoue D, Hijikata M, Goto K, Aly HH, Shimotohno K. Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. J Biol Chem 2007; 282: 32765-72.

  9. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon- a and ribavirin. Aliment Pharmacol Ther 2012; 36: 91-103.

  10. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

  11. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.




2020     |     www.medigraphic.com